May 4, 2023
Biden needs Lilly's new Alzheimer's treatment
By Noel S. Williams
President Trump enthusiastically touts his support of the Right to Try law, passed in May, 2018. Ironically, it may benefit one of his main political adversaries.
In what is a glorious development for elders and their caregivers, Eli Lilly’s Alzheimer’s treatment donanemab slowed the disease’s progression in a pivotal phase 3 trial.
A monthly antibody infusion reduced brain plaque associated with Alzheimer’s. In fact, patients in the trial demonstrated a 35% slower decline in memory.
As pointed out by Barrons’ Josh Nathan-Kazis, the drug’s efficacy marks, “an extraordinary moment in the decades-long struggle to find treatments for Alzheimer’s.”
Having missed the trial itself, Biden is a strong candidate for early donanemab infusions, pending FDA approval.
more
https://www.americanthinker.com/blog/2023/05/biden_needs_lillys_new_alzheimers_treatment.html
